NF-kappaB/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival
- PMID: 11521190
- DOI: 10.1038/sj.onc.1204607
NF-kappaB/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival
Abstract
In chronic myelogenous leukemia (CML), the oncogene bcr-abl encodes a dysregulated tyrosine kinase that inhibits apoptosis. We showed previously that human erythroleukemia K562 cells are resistant to antineoplastic drug (taxol)-induced apoptosis through the atypical protein kinase C iota isozyme (PKC iota), a kinase downstream of Bcr-Abl. The mechanism(s) by which PKC iota mediates cell survival to taxol is unknown. Here we demonstrate that PKC iota requires the transcription factor nuclear factor-kappaB (NF-kappaB) to confer cell survival. At apoptosis-inducing concentrations, taxol weakly induces IkappaB(alpha) proteolysis and NF-kappaB translocation in K562 cells, but potently induces its transcriptional activity. Inhibition of NF-kappaB activity (by blocking IkappaB(alpha) degradation) significantly sensitizes cells to taxol-induced apoptosis. Likewise, K562 cells expressing antisense PKC iota mRNA or kinase dead PKC iota (PKC iota-KD) are sensitized to taxol; these cells are rescued from apoptosis by NF-kappaB overexpression. Expression of constitutively active PKC iota (PKC iota-CA) upregulates NF-kappaB transactivation and rescues cells from apoptosis in the absence of Bcr-Abl tyrosine kinase activity. Using a chimeric GAL4-RelA transactivator, we find that taxol potently activates GAL4-RelA-dependent transcription. This activation was further upregulated by expression of PKC iota-CA and inhibited by expression of PKC iota-KD. Our results indicate that RelA transactivation is an important downstream target of the PKC iota-mediated Bcr-Abl signaling pathway and is required for resistance to taxol-induced apoptosis.
Similar articles
-
Protein kinase C iota: human oncogene, prognostic marker and therapeutic target.Pharmacol Res. 2007 Jun;55(6):487-97. doi: 10.1016/j.phrs.2007.04.015. Epub 2007 May 5. Pharmacol Res. 2007. PMID: 17570678 Free PMC article. Review.
-
Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation.Exp Hematol. 2003 Jun;31(6):504-11. doi: 10.1016/s0301-472x(03)00069-9. Exp Hematol. 2003. PMID: 12829026
-
Involvement of a novel Rac/RhoA guanosine triphosphatase-nuclear factor-kappaB inducing kinase signaling pathway mediating angiotensin II-induced RelA transactivation.Mol Endocrinol. 2007 Sep;21(9):2203-17. doi: 10.1210/me.2006-0465. Epub 2007 Jun 26. Mol Endocrinol. 2007. PMID: 17595324
-
Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells.Cancer Res. 2000 Aug 15;60(16):4426-32. Cancer Res. 2000. PMID: 10969788
-
The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias.Oncotarget. 2016 Oct 4;7(40):66287-66298. doi: 10.18632/oncotarget.11507. Oncotarget. 2016. PMID: 27563822 Free PMC article. Review.
Cited by
-
PKC phosphorylates HEXIM1 and regulates P-TEFb activity.Nucleic Acids Res. 2012 Oct;40(18):9160-70. doi: 10.1093/nar/gks682. Epub 2012 Jul 20. Nucleic Acids Res. 2012. PMID: 22821562 Free PMC article.
-
The Dual Roles of the Atypical Protein Kinase Cs in Cancer.Cancer Cell. 2019 Sep 16;36(3):218-235. doi: 10.1016/j.ccell.2019.07.010. Epub 2019 Aug 29. Cancer Cell. 2019. PMID: 31474570 Free PMC article. Review.
-
Protein kinase C iota: human oncogene, prognostic marker and therapeutic target.Pharmacol Res. 2007 Jun;55(6):487-97. doi: 10.1016/j.phrs.2007.04.015. Epub 2007 May 5. Pharmacol Res. 2007. PMID: 17570678 Free PMC article. Review.
-
Role of protein kinase C-iota in transformed non-malignant RWPE-1 cells and androgen-independent prostate carcinoma DU-145 cells.Cell Prolif. 2009 Apr;42(2):182-94. doi: 10.1111/j.1365-2184.2009.00582.x. Cell Prolif. 2009. PMID: 19243387 Free PMC article.
-
New Therapeutic Opportunities for the Treatment of Squamous Cell Carcinomas: A Focus on Novel Driver Kinases.Int J Mol Sci. 2021 Mar 11;22(6):2831. doi: 10.3390/ijms22062831. Int J Mol Sci. 2021. PMID: 33799513 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous